276 related articles for article (PubMed ID: 28318337)
1. The association of timing of disease-modifying drug initiation and relapse in patients with multiple sclerosis using electronic health records.
Corvino FA; Oliveri D; Phillips AL
Curr Med Res Opin; 2017 Jun; 33(6):1127-1132. PubMed ID: 28318337
[TBL] [Abstract][Full Text] [Related]
2. Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.
Lage MJ; Carroll CA; Fairman KA
J Med Econ; 2013 Sep; 16(9):1146-53. PubMed ID: 23844620
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with early initiation of disease-modifying drug treatment in newly-diagnosed patients with multiple sclerosis.
Edwards NC; Munsell M; Menzin J; Phillips AL
Curr Med Res Opin; 2018 Aug; 34(8):1389-1395. PubMed ID: 29493313
[TBL] [Abstract][Full Text] [Related]
4. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data.
Munday J; Greene M; Chang E; Hartry A; Yan T; Broder MS
Curr Med Res Opin; 2019 Jul; 35(7):1231-1239. PubMed ID: 30649965
[No Abstract] [Full Text] [Related]
5. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Lahoz R; Reynolds T; Korn JR
Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
[TBL] [Abstract][Full Text] [Related]
6. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.
Ivanova JI; Bergman RE; Birnbaum HG; Phillips AL; Stewart M; Meletiche DM
J Med Econ; 2012; 15(3):601-9. PubMed ID: 22376190
[TBL] [Abstract][Full Text] [Related]
7. Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS.
Houtchens MK; Edwards NC; Phillips AL
Neurology; 2018 Oct; 91(17):e1570-e1578. PubMed ID: 30266887
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
9. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
[TBL] [Abstract][Full Text] [Related]
10. Development and electronic health record validation of an algorithm for identifying patients with Duchenne muscular dystrophy in US administrative claims.
Schrader R; Posner N; Dorling P; Senerchia C; Chen Y; Beaverson K; Seare J; Garnier N; Walker V; Alvir J; Mahn M; Merla V; Zhang Y; Landis C; Buikema AR
J Manag Care Spec Pharm; 2023 Sep; 29(9):1033-1044. PubMed ID: 37610111
[No Abstract] [Full Text] [Related]
11. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs.
Birnbaum HG; Ivanova JI; Samuels S; Davis M; Cremieux PY; Phillips AL; Meletiche D
Curr Med Res Opin; 2009 Apr; 25(4):869-77. PubMed ID: 19232041
[TBL] [Abstract][Full Text] [Related]
12. Use of an early disease-modifying drug adherence measure to predict future adherence in patients with multiple sclerosis.
Kozma CM; Phillips AL; Meletiche DM
J Manag Care Spec Pharm; 2014 Aug; 20(8):800-7. PubMed ID: 25062073
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
[TBL] [Abstract][Full Text] [Related]
14. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records.
Earla JR; Hutton GJ; Thornton JD; Aparasu RR
Mult Scler Relat Disord; 2020 Oct; 45():102334. PubMed ID: 32629400
[TBL] [Abstract][Full Text] [Related]
15. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
[TBL] [Abstract][Full Text] [Related]
17. The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis.
Shelbaya A; Solem CT; Walker C; Wan Y; Johnson C; Cappelleri JC
Clinicoecon Outcomes Res; 2018; 10():213-222. PubMed ID: 29670383
[TBL] [Abstract][Full Text] [Related]
18. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study.
Margolis JM; Fowler R; Johnson BH; Kassed CA; Kahler K
BMC Neurol; 2011 Oct; 11():122. PubMed ID: 21974973
[TBL] [Abstract][Full Text] [Related]
19. Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs.
Yu AP; Ben-Hamadi R; Wu EQ; Kaltenboeck A; Bergman R; Xie J; Blum S; Erder MH
J Med Econ; 2011; 14(4):508-15. PubMed ID: 21692605
[TBL] [Abstract][Full Text] [Related]
20. The effect of age and sex on cost of inpatient facility encounters among patients with multiple sclerosis.
Kozma CM; Meletiche DM; Phillips AL
J Med Econ; 2015; 18(9):704-10. PubMed ID: 25913916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
